Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.38 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16747905 | 0.86 | TRPA1 (0.33) | IDO1ACP1P2RX3BCDIN3DDHODH | |
| SCHEMBL18094394 | 0.86 | DHODH (0.39) | IDO1HSD17B14ACP1MEN1CYP1A2 | |
| SCHEMBL18094405 | 0.83 | FLT3 (0.34) | HSD17B14P2RX3TRPA1MAP3K5FLT3 | |
| SCHEMBL18094397 | 0.83 | CYP11B1 (0.36) | HSD17B14ACP1MEN1CYP1A2CYP3A4 | |
| SCHEMBL18094380 | 0.79 | ROCK1 (0.38) | P2RX3MEN1KMT2ABCDIN3DTRPA1 | |
| SCHEMBL16747987 | 0.74 | KCNH2 (0.40) | — | |
| SCHEMBL16740204 | 0.74 | CYP11B2 (0.39) | IDO1CYP3A4BCDIN3DDHODH | |
| SCHEMBL16740212 | 0.73 | CSNK1D (0.36) | DHODHTRPA1 | |
| SCHEMBL16747856 | 0.72 | PKM (0.37) | ACP1MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16739933 | 0.72 | ABCG2 (0.37) | IDO1ACP1DHODHTRPA1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | IDO1 1325/4885HSD17B14 3671/4885ACP1 872/4885 |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | BMI1, BAZ2A, BAZ2B | IDO1 1325/4885HSD17B14 3671/4885ACP1 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.